A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Inclusion Criteria: * Diagnosis of Hodgkin's disease \[HD\] (excluding HIV-associated HD) * Patients must have read, understood, and provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained * Patients must have failed or relapsed following second line (i.e., salvage) chemotherapy or relapsed or failed following autologous stem cell transplant * ECOG Performance Status of 0-2 * Patients must have bi-measurable disease * At least 4 weeks since the last chemotherapy or radiation therapy with clinical evidence of recovery from any toxicity associated with such treatment * Life expectancy 12 weeks or greater * Screening laboratory values must be met * Patients on corticosteroids must be tapered off the medication 2 weeks prior to study drug administration and remain off corticosteroids until study completion. Exclusion Criteria: * Previous treatment with any anti-CD30 antibody * History of allogeneic transplant * Any tumor lesion 10cm or greater in diameter * Any other malignancy, excluding basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ. Any cancer from which the patient has been disease free for at least 5 years is permissible. * Any significant active or chronic infection * Apparent active or latent tuberculosis (TB) infection * Patients who are pregnant or nursing * Any underlying medical condition which, in the investigator's opinion, will make the administration of the study drug hazardous or obscure the interpretation of adverse events * Concomitant chemotherapy, steroids, investigational agents, other anti-HD biologics, or radiation therapy